Jon Congleton - Apr 11, 2025 Form 4 Insider Report for Mineralys Therapeutics, Inc. (MLYS)

Role: Chief Executive Officer, Director
Signature: /s/ Adam Levy, Attorney-in-fact
Stock symbol: MLYS
Transactions as of: Apr 11, 2025
Transactions value $: -$186,803
Form type: 4
Date filed: 4/15/2025, 08:33 PM
Previous filing: Feb 24, 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MLYS	Common Stock	Sale	-$187K	-15.3K	-1.75%	$12.19	862K	Apr 11, 2025	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id	Content
F1	This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.
F2	The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.0200 to $12.4087. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

Content

This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.0200 to $12.4087. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.